General “News” category

LCA Joins ACS CAN in Efforts to Protect Patient Access to Lifesaving Treatment

2019-01-17T20:05:01+00:00January 17th, 2019|Hot Topics, News|

Thursday, January 17 – Lung Cancer Alliance joins a long list of leading patient advocacy groups in support of American Cancer Society Cancer Action Network’s (ASC CAN) advertising campaign, urging the U.S. Administration and Congress not to limit patient access to lifesaving medications covered under Medicare, and to ensure the Six Protected Classes policy is preserved. The Six Protected Classes policy offers patients access to cutting-edge FDA-approved therapies for epilepsy, mental illness, cancer, HIV-Aids and organ transplants. A proposal from [...]

Get Well Soon Justice Ginsburg

2018-12-21T21:38:16+00:00December 21st, 2018|Hot Topics, News|

On behalf of the lung cancer community we serve, we send our best wishes for a speedy recovery to Supreme Court Justice Ruth Bader Ginsburg. According to a Supreme Court press release, Justice Ginsburg is now resting comfortably after undergoing a pulmonary lobectomy today. Two nodules, found to be malignant on initial pathology evaluation, were removed. The nodules were incidental findings from tests used to diagnose and treat Justice Ginsburg’s recent rib fractures from a November 7 fall. “We are relieved [...]

A Message from LCA’s President

2018-12-19T16:31:37+00:00December 19th, 2018|Hot Topics, News|

To the Lung Cancer Community, As 2018 prepares to come to a close, let’s take this moment to reflect upon what we have accomplished to improve survivorship, provide support and bring our community together in a lasting and meaningful way. Together we secured millions more dollars in federal research funding, helped hundreds of patients navigate clinical trials and get molecular testing, launched a screening campaign to help people talk with their physicians about lung cancer screening and their risk, enhanced [...]

New Combination Treatment Approved for Non-Small Cell Lung Cancer

2018-12-07T14:39:55+00:00December 7th, 2018|Hot Topics, News|

The Food and Drug Administration (FDA) approved atezolizumab (TECENTRIQ®), an immunotherapy drug, in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations. This is the first four drug combination treatment approved for lung cancer. Click here to learn more.

LCA partners with GRAIL, UCL, and ULCH on Newly Announced SUMMIT Study

2018-12-04T00:24:30+00:00December 4th, 2018|Hot Topics, News|

Monday, December 3, 2018 –Today, Lung Cancer Alliance, in collaboration with GRAIL, Inc., a healthcare company focused on the early detection of cancer, UCL (University College London) and University College London Hospitals National Health Service (NHS) Foundation Trust (UCLH) announced plans to initiate the SUMMIT study in early 2019. SUMMIT, which will be conducted in the United Kingdom, is a prospective, observational, longitudinal, cohort study designed to enroll approximately 50,000 men and women age 50 to 77 years who do [...]

4 Simple Steps to Finding the Right Clinical Trial

2018-11-29T18:27:09+00:00November 28th, 2018|Hot Topics, News|

Today, there are more options for lung cancer treatment than ever before. Some are already approved and available. Others are only available through clinical trials. With so many clinical trials out there, the process of finding one can seem daunting. Not to worry! We have you covered. Here are four steps to finding the right clinical trial for you. 1) GATHER INFORMATION: Each clinical trial is looking for a very specific patient and has a number of criteria that you [...]

FDA Approves Targeted Therapy for Solid Tumors with NTRK Gene

2018-11-27T14:40:07+00:00November 27th, 2018|Hot Topics, News|

Tuesday, November 27, 2018 - The U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. and Bayer) for adult and pediatric patients with advanced solid tumors, including lung cancer, that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known resistance mutation. These gene fusions can be in the NTRK1, NTRK2, or NTRK3 genes. Patients with advanced lung cancer who had NTRK gene fusions were included in the research that led to this [...]

2018 Lung Cancer Support Group Facilitator Award

2018-11-05T20:09:24+00:00November 5th, 2018|Hot Topics, News|

Monday, November 5, 2018 -- Today, Lung Cancer Alliance presented the 2018 Lung Cancer Support Group Facilitator Award to Catherine Paykin, LCSW-R, who runs a support group at New York University Perlmutter Cancer Center. The Lung Cancer Support Group Facilitator Award recognizes the uncommon dedication of a support group facilitator. Members from Catherine's support group nominated her for the award. Miranda Goff, Lung Cancer Alliance, was in New York City to present the award to Catherine. We are incredibly grateful for all [...]

FDA Approves New Treatment for ALK+ NSCLC Patients

2018-11-05T14:35:44+00:00November 2nd, 2018|Hot Topics, News|

Friday, November 2, 2018 – Today the Food and Drug Administration (FDA) granted accelerated approval to lorlatinib (LORBRENA) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.Click here to learn more. 

LCA Named 2018 Top Rated Nonprofit

2018-11-02T19:21:49+00:00November 2nd, 2018|Hot Topics, News|

Friday, November 2, 2018 - Today Lung Cancer Alliance was named a “2018 Top-Rated Nonprofit” by GreatNonprofits, the leading provider of user reviews of charities and nonprofits. The Top-Rated Nonprofit Award is based on the rating and number of reviews that Lung Cancer Alliance received from volunteers, donors and aid recipients. These are the only awards for nonprofits determined by those who have direct experience with the charities – as donors, volunteers and recipients of aid. “Lung Cancer Alliance is a great [...]